Bio-Techne
TECH
#2284
Rank
NZ$13.64 B
Marketcap
NZ$87.20
Share price
4.61%
Change (1 day)
-18.58%
Change (1 year)
Bio-Techne Corporation is an American holding company for biotechnology and clinical diagnostic brands. The company's brands portfolio includes R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, Exosome Diagnostics, BiosPacific, Cliniqa, Advanced Cell Diagnostics, RNA Medical, Bionostics and BostonBiochem.

P/E ratio for Bio-Techne (TECH)

P/E ratio as of March 2026 (TTM): 98.2

According to Bio-Techne's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 98.1923. At the end of 2024 the company had a P/E ratio of 71.7.

P/E ratio history for Bio-Techne from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202471.733.13%
202353.99.97%
202249.0-48.21%
202194.638.49%
202068.363.25%
201941.8-24.26%
201855.235.66%
201740.7-12.15%
201646.346.5%
201531.616.09%
201427.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
26.6-72.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
29.0-70.45%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
36.8-62.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Danaher
DHR
38.5-60.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Qiagen
QGEN
21.1-78.49%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Enzo Biochem
ENZB
-3.33-103.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Rad Laboratories
BIO
-11.1-111.29%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.